Tamoxifen

The SOLTI VALENTINE trial showed neoadjuvant patritumab deruxtecan with or without letrozole sustained responses with fewer toxicities vs multi-agent chemotherapy in breast cancer.

Immediate surgery reduced local recurrence in elderly breast cancer patients vs deferred surgery, with benefits in distant recurrence and mortality apparent over long follow-up. Tamoxifen with surgery lowered local recurrence rates significantly compared to tamoxifen alone. Immediate surgery had minimal impact on distant recurrence or breast cancer mortality within a year. All-cause mortality rates were slightly lower with surgery plus tamoxifen. The analysis emphasized the importance of long-term follow-up in assessing benefits of local therapy.

Exclusive postoperative radiation therapy improved health-related quality of life and reduced treatment-related adverse events compared to adjuvant endocrine therapy in older patients with stage I luminal-like breast cancer at 24 months, according to the EUROPA trial. Radiation therapy showed better outcomes in various QLQ-C30 function and symptom scales, fewer treatment-emergent adverse events, and no ipsilateral breast tumor recurrence or breast cancer-related death at 24 months.